Trekrezan and PGC‑1α expression in rat muscle — RU2460524C1
Patent disclosure · 2012
- What the patent describes
- Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.
- Reported evidence
- In 60 rats, the patent reports swim times of 33.50 minutes with saline, 48.00 with 10 mg/kg Trekrezan and 52.30 with 25 mg/kg.
Loaded swimming time · 33.50 ± 1.70 vs 48.00 ± 2.40 and 52.30 ± 2.60 minutes · Saline vs 10 and 25 mg/kg, respectively
Reported patent results
Reported findings
In 60 rats, the patent reports swim times of 33.50 minutes with saline, 48.00 with 10 mg/kg Trekrezan and 52.30 with 25 mg/kg.
Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.
Population or model Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Loaded swimming time | 33.50 ± 1.70 vs 48.00 ± 2.40 and 52.30 ± 2.60 minutes | Saline vs 10 and 25 mg/kg, respectively |
| Hanging-grid time | 11.45 ± 0.58 vs 15.45 ± 0.77 and 16.35 ± 0.82 minutes | Same group order |
| PGC‑1α mRNA relative to β-actin | 0.90 ± 0.10 vs 1.72 ± 0.15 and 1.90 ± 0.20 | Same group order |
| Relative mitochondrial DNA per diploid genome | 0.90 ± 0.10 vs 1.15 ± 0.10 and 2.25 ± 0.20 | Same group order |
Rat exercise and muscle measures reported in Tables 1–3
| Measure | Saline | 10 mg/kg | 25 mg/kg |
|---|---|---|---|
| Loaded swimming time (minutes) | 33.50 ± 1.70 | 48.00 ± 2.40 | 52.30 ± 2.60 |
| Hanging-grid time (minutes) | 11.45 ± 0.58 | 15.45 ± 0.77 | 16.35 ± 0.82 |
| Relative PGC‑1α/β-actin mRNA | 0.90 ± 0.10 | 1.72 ± 0.15 | 1.90 ± 0.20 |
| Relative mtDNA per diploid genome | 0.90 ± 0.10 | 1.15 ± 0.10 | 2.25 ± 0.20 |
Values with uncertainty as printed in the patent. The animal count of 60 is for the experiment as a whole.
The disclosed RNA and DNA assays are indirect mitochondrial measures. The experiment does not show how Trekrezan affects human endurance.
Source for these results ↗ · Reviewed 2026-11-15
Patent claims and provenance
Use. Claims a Trekrezan use involving expression of the mitochondrial biogenesis regulator PGC‑1α.
The supporting experiment used rats. The filing reports relative muscle markers and exercise tests. Direct mitochondrial respiration and human outcomes were outside the experiment.
- Publication
- RU2460524C1 ↗ · 2012-09-10
- Earliest priority / filing
- 2011-04-12 / 2011-04-12
- Original applicant / assignee
- Maksud M. Rasulov
- Indexed status
- Not shown; official status unverified · checked 2026-11-15
- Patent family
- 46938825 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Средство, стимулирующее экспрессию гена коактиватора PGC-1α
Inventors: M. M. Rasulov; M. K. Nurbekov; M. G. Voronkov; S. N. Bobkova; O. A. Belikova; M. V. Zvereva; N. P. Shimanovskaya; O. A. Speranskaya.
Study limitations and source details
Study limitations
- The supporting experiment used rats. The filing reports relative muscle markers and exercise tests. Direct mitochondrial respiration and human outcomes were outside the experiment.
- The disclosed RNA and DNA assays are indirect mitochondrial measures. The experiment does not show how Trekrezan affects human endurance.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Related publications may describe some of the same participants or experiments.
Source details
Patent publication · Original patent text and indexed metadata
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sources checked
Citation
Published
M. M. Rasulov, M. K. Nurbekov, M. G. Voronkov, S. N. Bobkova, O. A. Belikova, M. V. Zvereva, N. P. Shimanovskaya, O. A. Speranskaya. Trekrezan and PGC‑1α expression in rat muscle — RU2460524C1 RU2460524C1 · patent family 46938825